Koca Tuba, Koçyiğit Burhan, Seyithanoğlu Muhammet, Berk Ejder
Department of Physical Medicine and Rehabilitation, Kahramanmaraş Sütçü İmam University Faculty of Medicine, Kahramanmaraş, Turkey.
Department of Clinic Biochemistry, Kahramanmaraş Sütçü İmam University Faculty of Medicine, Kahramanmaraş, Turkey.
Arch Rheumatol. 2019 Jan 23;34(4):419-425. doi: 10.5606/ArchRheumatol.2019.7236. eCollection 2019 Dec.
This study aims to analyze the G-protein coupled estrogen receptor (GPER/GPR30) activity in patients with fibromyalgia syndrome (FMS).
We enrolled 40 female patients with FMS (mean age 42.9±11.2 years; range, 18 to 64 years) diagnosed according to the 2010 American College of Rheumatology classification criteria and 30 age- and body mass index-matched female healthy controls (mean age 43.7±13.6 years; range, 19 to 64 years). Sex hormones of patients (morning) including estradiol, follicle stimulating hormone, luteinizing hormone, and prolactin (PRL) were recorded. FMS severity was assessed by Fibromyalgia Impact Questionnaire (FIQ). Serum GPER levels were measured by using a quantitative sandwich enzyme-linked immunosorbent assay method with a commercial kit.
G-protein coupled estrogen receptor levels were 0.11 (0.02-0.9) ng/mL in the FMS patients and 0.059 (0.01-0.13) ng/mL in controls, with a statistically significant difference (p=0.037). GPER levels were positively correlated with age and negatively correlated with PRL, while they were not correlated with FIQ. Differential diagnosis for FMS with receiver operating characteristic (ROC) analysis for the serum GPER levels was statistically significant (area under the ROC curve: 0.653, confidence interval: 0.522-0.785, p=0.029). High values indicated FMS, with a threshold of >0.075, sensitivity of 60%, and specificity of 60%.
The GPER levels of FMS patients were higher than those of the controls. Thus, GPER levels may be considered as a biomarker in the diagnosis of FMS independent of disease severity.
本研究旨在分析纤维肌痛综合征（FMS）患者中G蛋白偶联雌激素受体（GPER/GPR30）的活性。
我们纳入了40例根据2010年美国风湿病学会分类标准诊断为FMS的女性患者（平均年龄42.9±11.2岁；范围18至64岁）以及30例年龄和体重指数匹配的女性健康对照者（平均年龄43.7±13.6岁；范围19至64岁）。记录患者早晨的性激素，包括雌二醇、促卵泡激素、促黄体生成素和催乳素（PRL）。通过纤维肌痛影响问卷（FIQ）评估FMS的严重程度。使用商业试剂盒通过定量夹心酶联免疫吸附测定法测量血清GPER水平。
FMS患者的G蛋白偶联雌激素受体水平为0.11（0.02 - 0.9）ng/mL，对照组为0.059（0.01 - 0.13）ng/mL，差异具有统计学意义（p = 0.037）。GPER水平与年龄呈正相关，与PRL呈负相关，而与FIQ无关。血清GPER水平的受试者工作特征（ROC）分析对FMS的鉴别诊断具有统计学意义（ROC曲线下面积：0.653，置信区间：0.522 - 0.785，p = 0.029）。高值表明为FMS，阈值>0.075，敏感性为60%，特异性为60%。
FMS患者的GPER水平高于对照组。因此，GPER水平可被视为独立于疾病严重程度的FMS诊断生物标志物。
